Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

Highly Sensitized Patients on Waiting List for Kidney Transplantation Clinical Trial

Official title: A Phase 2 Open-label, Prospective, Randomized Study of Inebilizumab, VIB4920, or the Combination to Evaluate Safety and Tolerability in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

Status Withdrawn

Clinical Trial Summary

Viela Bio is conducting an open-label, randomized study of inebilizumab, VIB4920, or the combination as part of a multi-center study in highly sensitized patients on the deceased donor waiting list for kidney transplantation. Eligible subjects will be randomized to one of three treatment arms, administered the investigational products as an intervention and subsequently followed for safety.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Death
• Highly Sensitized Patients on Waiting List for Kidney Transplantation

• NCT number: NCT04174677
• Study type: Interventional
• Source: Viela Bio (acquired by Horizon Therapeutics)
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 27, 2019
• Completion date: April 2022